Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count.

IF 1.9 3区生物学 Q2 MARINE & FRESHWATER BIOLOGY

Diatom Research Pub Date : 2022-08-24 DOI:10.1093/cid/ciac238

Andrea Antinori, Stefania Cicalini, Silvia Meschi, Veronica Bordoni, Patrizia Lorenzini, Alessandra Vergori, Simone Lanini, Lidya De Pascale, Giulia Matusali, Davide Mariotti, Alessandro Cozzi Lepri, Paola Gallì, Carmela Pinnetti, Roberta Gagliardini, Valentina Mazzotta, Ilaria Mastrorosa, Susanna Grisetti, Francesca Colavita, Eleonora Cimini, Elisabetta Grilli, Rita Bellagamba, Daniele Lapa, Alessandra Sacchi, Alessandra Marani, Carlo Cerini, Caterina Candela, Marisa Fusto, Vincenzo Puro, Concetta Castilletti, Chiara Agrati, Enrico Girardi, Francesco Vaia

{"title":"Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count.","authors":"Andrea Antinori, Stefania Cicalini, Silvia Meschi, Veronica Bordoni, Patrizia Lorenzini, Alessandra Vergori, Simone Lanini, Lidya De Pascale, Giulia Matusali, Davide Mariotti, Alessandro Cozzi Lepri, Paola Gallì, Carmela Pinnetti, Roberta Gagliardini, Valentina Mazzotta, Ilaria Mastrorosa, Susanna Grisetti, Francesca Colavita, Eleonora Cimini, Elisabetta Grilli, Rita Bellagamba, Daniele Lapa, Alessandra Sacchi, Alessandra Marani, Carlo Cerini, Caterina Candela, Marisa Fusto, Vincenzo Puro, Concetta Castilletti, Chiara Agrati, Enrico Girardi, Francesco Vaia","doi":"10.1093/cid/ciac238","DOIUrl":null,"url":null,"abstract":"Background: Data on SARS-CoV-2 vaccine immunogenicity in PLWH are currently limited. Aim of the study was to investigate immunogenicity according to current CD4 T-cell count.Methods: PLWH on ART attending a SARS-CoV-2 vaccination program, were included in a prospective immunogenicity evaluation after receiving BNT162b2 or mRNA-1273. Participants were stratified by current CD4 T-cell count (poor CD4 recovery, PCDR: <200/mm3; intermediate CD4 recovery, ICDR: 200-500/mm3; high CD4 recovery, HCDR: >500/mm3). RBD-binding IgG, SARS-CoV-2 neutralizing antibodies (nAbs) and IFN-γ release were measured. As control group, HIV-negative healthcare workers (HCWs) were used.Findings: Among 166 PLWH, after 1 month from the booster dose, detectable RBD-binding IgG were elicited in 86.7% of PCDR, 100% of ICDR, 98.7% of HCDR, and a neutralizing titre ≥1:10 elicited in 70.0%, 88.2%, and 93.1%, respectively. Compared to HCDR, all immune response parameters were significantly lower in PCDR. After adjusting for confounders, current CD4 T-cell <200/mm3 significantly predicted a poor magnitude of anti-RDB, nAbs and IFN-γ response. As compared with HCWs, PCDR elicited a consistently reduced immunogenicity for all parameters, ICDR only a reduced RBD-binding antibody response, whereas HCDR elicited a comparable immune response for all parameters.Conclusion: Humoral and cell-mediated immune response against SARS-CoV-2 were elicited in most of PLWH, albeit significantly poorer in those with CD4 T-cell <200/mm3 versus those with >500 cell/mm3 and HIV-negative controls. A lower RBD-binding antibody response than HCWs was also observed in PLWH with CD4 T-cell 200-500/mm3, whereas immune response elicited in PLWH with a CD4 T-cell >500/mm3 was comparable to HIV-negative population.","PeriodicalId":11199,"journal":{"name":"Diatom Research","volume":"21 1","pages":"e552-e563"},"PeriodicalIF":1.9000,"publicationDate":"2022-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047161/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diatom Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/cid/ciac238","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MARINE & FRESHWATER BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Data on SARS-CoV-2 vaccine immunogenicity in PLWH are currently limited. Aim of the study was to investigate immunogenicity according to current CD4 T-cell count.

Methods: PLWH on ART attending a SARS-CoV-2 vaccination program, were included in a prospective immunogenicity evaluation after receiving BNT162b2 or mRNA-1273. Participants were stratified by current CD4 T-cell count (poor CD4 recovery, PCDR: <200/mm3; intermediate CD4 recovery, ICDR: 200-500/mm3; high CD4 recovery, HCDR: >500/mm3). RBD-binding IgG, SARS-CoV-2 neutralizing antibodies (nAbs) and IFN-γ release were measured. As control group, HIV-negative healthcare workers (HCWs) were used.

Findings: Among 166 PLWH, after 1 month from the booster dose, detectable RBD-binding IgG were elicited in 86.7% of PCDR, 100% of ICDR, 98.7% of HCDR, and a neutralizing titre ≥1:10 elicited in 70.0%, 88.2%, and 93.1%, respectively. Compared to HCDR, all immune response parameters were significantly lower in PCDR. After adjusting for confounders, current CD4 T-cell <200/mm3 significantly predicted a poor magnitude of anti-RDB, nAbs and IFN-γ response. As compared with HCWs, PCDR elicited a consistently reduced immunogenicity for all parameters, ICDR only a reduced RBD-binding antibody response, whereas HCDR elicited a comparable immune response for all parameters.

Conclusion: Humoral and cell-mediated immune response against SARS-CoV-2 were elicited in most of PLWH, albeit significantly poorer in those with CD4 T-cell <200/mm3 versus those with >500 cell/mm3 and HIV-negative controls. A lower RBD-binding antibody response than HCWs was also observed in PLWH with CD4 T-cell 200-500/mm3, whereas immune response elicited in PLWH with a CD4 T-cell >500/mm3 was comparable to HIV-negative population.

查看原文本刊更多论文

根据目前的 CD4 T 淋巴细胞计数，对接受抗逆转录病毒疗法的人类免疫缺陷病毒感染者接种严重急性呼吸系统综合征冠状病毒 2 (SARS-CoV-2) mRNA 疫苗引起的体液和细胞免疫反应。

背景：目前有关 PLWH 中 SARS-CoV-2 疫苗免疫原性的数据有限。本研究旨在根据目前的 CD4 T 细胞数调查免疫原性：方法：参加 SARS-CoV-2 疫苗接种计划的接受抗逆转录病毒疗法的 PLWH 在接种 BNT162b2 或 mRNA-1273 后被纳入前瞻性免疫原性评估。参与者按目前的 CD4 T 细胞计数进行分层（CD4 恢复不佳，PCDR：500/mm3）。检测RBD结合IgG、SARS-CoV-2中和抗体（nAbs）和IFN-γ释放。对照组为艾滋病毒阴性的医护人员（HCWs）：在 166 名 PLWH 中，加强剂量 1 个月后，86.7% 的 PCDR、100% 的 ICDR 和 98.7% 的 HCDR 可检测到 RBD 结合 IgG，中和滴度≥1:10 的分别占 70.0%、88.2% 和 93.1%。与 HCDR 相比，PCDR 的所有免疫反应参数都明显降低。在对混杂因素进行调整后，目前的 CD4 T 细胞大多数 PLWH 都能产生针对 SARS-CoV-2 的体液和细胞介导免疫反应，但 CD4 T 细胞为 500 cells/mm3 的 PLWH 和 HIV 阴性对照者的反应明显较差。在 CD4 T 细胞为 200-500 个/立方毫米的 PLWH 中，也观察到 RBD 结合抗体反应低于 HCWs，而在 CD4 T 细胞大于 500 个/立方毫米的 PLWH 中，引起的免疫反应与 HIV 阴性人群相当。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diatom Research 生物-海洋与淡水生物学

CiteScore

2.70

自引率

16.70%

发文量

审稿时长

>12 weeks

期刊介绍： Diatom Research is the journal of the International Society for Diatom Research. The journal is published quarterly, in March, June, September and December, and welcomes manuscripts on any aspect of diatom biology. In addition to full-length papers, short notes and reviews of recent literature are published which need not contain all the sections required for full-length papers; we see these as being necessary to record information which is of interest but which cannot be followed up in detail. Discursive “Opinion” papers are encouraged which would not necessarily follow the normal lay-out. If extremely long papers are to be offered, the author(s) should contact the editors first to discuss any problems. Book reviews, obituaries and meeting reports can be published. All papers will be subject to critical review by the editors and referees, as appropriate to their content. Papers will be accepted in English only.